Which of the following Parasympathomimetic drug is used to treat Xerostomia
Parasympathomimetics are drugs that stimulate the parasympathetic nervous system. The parasympathetic system is responsible for rest-and-digest functions, and one of its effects is stimulating salivation. So, the question is asking which of these drugs is used to treat dry mouth by increasing saliva production.
The main parasympathomimetics I can think of are pilocarpine and cevimeline. Both are cholinergic agonists. Pilocarpine is a muscarinic agonist, which acts on salivary glands to stimulate saliva. Cevimeline is similar but more selective for M3 receptors. Both are used for xerostomia, especially in patients who have undergone radiation therapy or have Sjögren's syndrome.
Now, looking at the options, the correct answer would be either A, B, C, or D. But since the options aren't provided, I need to assume the standard ones. Common distractors might include drugs like atropine (which is an anticholinergic and would make dry mouth worse), or maybe other cholinergic drugs like neostigmine, but neostigmine is an acetylcholinesterase inhibitor, not a direct agonist. Another possible wrong option could be a sympathomimetic like epinephrine, which doesn't stimulate salivation.
So, the correct answer is likely pilocarpine or cevimeline. The explanation should highlight that they are muscarinic agonists used to stimulate salivation. The incorrect options would be other classes of drugs that don't have this effect. The clinical pearl would be to remember that these drugs are used in specific cases where salivation is reduced, and to avoid anticholinergics in such patients.
**Core Concept**
Xerostomia (dry mouth) is managed using parasympathomimetics that stimulate salivary secretion. **Pilocarpine** and **cevimeline** are direct-acting cholinergic agonists that activate **muscarinic receptors (M3)** in salivary glands, enhancing saliva production.
**Why the Correct Answer is Right**
Pilocarpine is a **muscarinic receptor agonist** that selectively targets **M3 receptors** in salivary glands, mimicking acetylcholine’s action. This activates intracellular pathways (e.g., **calcium mobilization**) to increase saliva secretion. It is FDA-approved for xerostomia in Sjögren’s syndrome and post-radiation patients. Cevimeline is an alternative with similar mechanism but higher M3 selectivity.
**Why Each Wrong Option is Incorrect**
**Option A:** Atropine is an **anticholinergic** that inhibits salivation, worsening xerostomia.
**Option B:** Epinephrine is a **sympathomimetic**, stimulating alpha-adrenergic receptors with no salivary effect.
**Option C:** Neostigmine is an **acetyl